Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)

NCT00385164 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT00385164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
AHS Cancer Control Alberta
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2006
Completion date
Not reported
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms, positron emission tomography